ETR:MOR

MorphoSys Stock Forecast, Price & News

€75.58
-1.86 (-2.40 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
€75.48
Now: €75.58
€77.40
50-Day Range
€72.90
MA: €78.63
€85.96
52-Week Range
€71.62
Now: €75.58
€125.20
Volume220,199 shs
Average Volume153,687 shs
Market Capitalization$2.48 billion
P/E Ratio25.44
Dividend YieldN/A
BetaN/A
MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
MorphoSys logo

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+49-89-899270
Employees615
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$327.70 million
Cash Flow€33.28 per share
Book Value€18.97 per share

Profitability

Miscellaneous

Market Cap$2.48 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableNot Optionable

Headlines

MorphoSys AG launches €325M convertible bonds
October 13, 2020 |  seekingalpha.com
MorphoSys's CFO to step down
October 1, 2020 |  seekingalpha.com
See More Headlines

MarketRank

Overall MarketRank

1.53 out of 5 stars

Analyst Opinion: 4.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
€75.58
-1.86 (-2.40 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MOR News and Ratings via Email

Sign-up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MorphoSys (ETR:MOR) Frequently Asked Questions

Is MorphoSys a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MorphoSys stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOR, but not buy additional shares or sell existing shares.
View analyst ratings for MorphoSys
or view top-rated stocks.

What stocks does MarketBeat like better than MorphoSys?

Wall Street analysts have given MorphoSys a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MorphoSys wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is MorphoSys' next earnings date?

MorphoSys is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for MorphoSys
.

How has MorphoSys' stock been impacted by Coronavirus (COVID-19)?

MorphoSys' stock was trading at €91.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MOR shares have decreased by 17.0% and is now trading at €75.58.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MOR?

9 equities research analysts have issued 1 year price objectives for MorphoSys' stock. Their forecasts range from €88.00 to €140.00. On average, they expect MorphoSys' share price to reach €109.78 in the next year. This suggests a possible upside of 45.2% from the stock's current price.
View analysts' price targets for MorphoSys
or view top-rated stocks among Wall Street analysts.

Who are MorphoSys' key executives?

MorphoSys' management team includes the following people:
  • Dr. Jean-Paul Kress, Chairman of Management Board, MD & CEO (Age 56, Pay $2.06M)
  • Dr. Malte Peters M.D., Chief R&D Officer and Member of the Management Board (Age 59, Pay $1.18M)
  • Dr. Roland Wandeler Ph.D., COO & Member of Management Board (Age 49, Pay $1.19M)
  • Mr. Sung H. Lee, CFO & Member of Management Board (Age 51)
  • Mr. Klaus De Wall, Head of Accounting & Tax
  • Ms. Lara Smith Weber, Head of Controlling, Corp. Fin. & Corp. Devel.
  • Dr. Margit Urban, Head of Discovery Alliances & Technologies
  • Dr. Anja Pomrehn, Sr. VP & Head of Investor Relations
  • Dr. Armin Weidmann, Head of Compliance and Quality Assurance
  • Ms. Charlotte Lohmann, Sr. VP & Gen. Counsel (Age 51)

Who are some of MorphoSys' key competitors?

What other stocks do shareholders of MorphoSys own?

What is MorphoSys' stock symbol?

MorphoSys trades on the ETR under the ticker symbol "MOR."

What is MorphoSys' stock price today?

One share of MOR stock can currently be purchased for approximately €75.58.

How much money does MorphoSys make?

MorphoSys has a market capitalization of $2.48 billion and generates $327.70 million in revenue each year.

How many employees does MorphoSys have?

MorphoSys employs 615 workers across the globe.

What is MorphoSys' official website?

The official website for MorphoSys is www.morphosys.de.

Where are MorphoSys' headquarters?

MorphoSys is headquartered at Semmelweisstr. 7, PLANEGG, 82152, Germany.

How can I contact MorphoSys?

MorphoSys' mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-899270.


This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.